Modality
Multispecific
MOA
CDK4/6i
Target
Menin
Pathway
NF-κB
Gastric Ca
Development Pipeline
Preclinical
~Dec 2016
→ ~Mar 2018
Phase 1
~Jun 2018
→ ~Sep 2019
Phase 2
Dec 2019
→ Feb 2029
Phase 2Current
NCT08523633
371 pts·Gastric Ca
2024-10→2029-02·Not yet recruiting
NCT07350204
1,532 pts·Gastric Ca
2019-12→2027-10·Recruiting
1,903 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2027-10-031.5y awayPh2 Data· Gastric Ca
2029-02-142.9y awayPh2 Data· Gastric Ca
Trial Timeline
Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2
P2
Recruit…
P2
Not yet…
Catalysts
Ph2 Data
2027-10-03 · 1.5y away
Gastric Ca
Ph2 Data
2029-02-14 · 2.9y away
Gastric Ca
RecruitingNot yet recruiting|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT08523633 | Phase 2 | Gastric Ca | Not yet recr... | 371 | eGFR |
| NCT07350204 | Phase 2 | Gastric Ca | Recruiting | 1532 | LiverFat |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-5767 | Pfizer | Phase 1/2 | BET | |
| LLY-8369 | Eli Lilly | Approved | Menin | |
| RHH-1969 | Roche | Approved | BET | |
| NVS-1475 | Novartis | Phase 2 | Menin | |
| Ivocapivasertib | Bristol-Myers Squibb | Phase 1 | BET | |
| Zorimavacamten | Bristol-Myers Squibb | Preclinical | Cl18.2 | |
| Fixatenlimab | GSK | Phase 1/2 | JAK1 | |
| VRT-4938 | Vertex Pharma | Preclinical | HER2 | |
| VRT-9481 | Vertex Pharma | Phase 1/2 | Menin | |
| VRT-5441 | Vertex Pharma | Phase 3 | GLP-1R |